Biovie R&D Spending Growth & History (BIVI)
Biovie's r&d spending was $14.0M for fiscal 2026.
View full Biovie company overviewBiovie annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-06-30 | $14.0M | $4.7M | +50.67% |
| 2025 | 2025-06-30 | $9.3M | −$13.8M | −59.88% |
| 2024 | 2024-06-30 | $23.1M | −$10.2M | −30.63% |
| 2023 | 2023-06-30 | $33.3M | $16.0M | +92.95% |
| 2022 | 2022-06-30 | $17.3M | $14.7M | +578.22% |
| 2021 | 2021-06-30 | $2.5M | $1.4M | +121.16% |
| 2020 | 2020-06-30 | $1.2M | $142,481 | +14.13% |
| 2019 | 2019-06-30 | $1.0M | $637,248 | +171.83% |
| 2018 | 2018-06-30 | $370,852 | −$95,502 | −20.48% |
| 2017 | 2017-06-30 | $466,354 | $428,453 | +1130.45% |
| 2016 | 2016-06-30 | $37,901 | $33,705 | +803.27% |
| 2015 | 2015-06-30 | $4,196 | −$45,223 | −91.51% |
| 2014 | 2014-06-30 | $49,419 | — | — |
Biovie quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-06-30 | $3.6M | $2.4M | +191.80% |
| Q3 2026 | 2026-03-31 | $3.2M | $1.8M | +136.21% |
| Q2 2026 | 2025-12-31 | $4.3M | −$435,327 | −9.25% |
| Q1 2026 | 2025-09-30 | $2.9M | $946,172 | +47.54% |
| Q4 2025 | 2025-06-30 | $1.2M | −$827,287 | −40.28% |
| Q3 2025 | 2025-03-31 | $1.3M | −$4.4M | −76.41% |
| Q2 2025 | 2024-12-31 | $4.7M | −$1.8M | −27.29% |
| Q1 2025 | 2024-09-30 | $2.0M | −$6.9M | −77.58% |
| Q4 2024 | 2024-06-30 | $2.1M | −$6.2M | −75.25% |
| Q3 2024 | 2024-03-31 | $5.7M | −$5.5M | −49.09% |
| Q2 2024 | 2023-12-31 | $6.5M | −$562,636 | −8.00% |
| Q1 2024 | 2023-09-30 | $8.9M | $2.1M | +31.10% |
| Q4 2023 | 2023-06-30 | $8.3M | $2.4M | +41.33% |
| Q3 2023 | 2023-03-31 | $11.2M | $7.6M | +213.01% |
| Q2 2023 | 2022-12-31 | $7.0M | $2.3M | +49.20% |
| Q1 2023 | 2022-09-30 | $6.8M | $3.7M | +118.75% |
| Q4 2022 | 2022-06-30 | $5.9M | $5.2M | +720.15% |
| Q3 2022 | 2022-03-31 | $3.6M | $2.8M | +353.05% |
| Q2 2022 | 2021-12-31 | $4.7M | $3.8M | +402.47% |
| Q1 2022 | 2021-09-30 | $3.1M | $3.0M | +2966.75% |
| Q4 2021 | 2021-06-30 | $716,056 | $606,688 | +554.72% |
| Q3 2021 | 2021-03-31 | $789,577 | $436,379 | +123.55% |
| Q2 2021 | 2020-12-31 | $938,101 | $591,587 | +170.73% |
| Q1 2021 | 2020-09-30 | $100,914 | −$240,587 | −70.45% |
| Q4 2020 | 2020-06-30 | $109,368 | −$166,358 | −60.33% |
| Q3 2020 | 2020-03-31 | $353,198 | $21,364 | +6.44% |
| Q2 2020 | 2019-12-31 | $346,514 | $140,495 | +68.20% |
| Q1 2020 | 2019-09-30 | $341,501 | $146,980 | +75.56% |
| Q4 2019 | 2019-06-30 | $275,726 | $179,989 | +188.00% |
| Q3 2019 | 2019-03-31 | $331,834 | $285,414 | +614.85% |
| Q2 2019 | 2018-12-31 | $206,019 | $19,178 | +10.26% |
| Q1 2019 | 2018-09-30 | $194,521 | $152,667 | +364.76% |
| Q4 2018 | 2018-06-30 | $95,737 | $5,255 | +5.81% |
| Q3 2018 | 2018-03-31 | $46,420 | −$73,623 | −61.33% |
| Q2 2018 | 2017-12-31 | $186,841 | $58,282 | +45.33% |
| Q1 2018 | 2017-09-30 | $41,854 | −$85,416 | −67.11% |
| Q4 2017 | 2017-06-30 | $90,482 | — | — |
| Q3 2017 | 2017-03-31 | $120,043 | — | — |
| Q2 2017 | 2016-12-31 | $128,559 | — | — |
| Q1 2017 | 2016-09-30 | $127,270 | $127,270 | — |
| Q1 2016 | 2015-09-30 | $0 | −$3,400 | — |
| Q4 2015 | 2015-06-30 | $796 | — | — |
| Q3 2015 | 2015-03-31 | $0 | −$19,409 | — |
| Q2 2015 | 2014-12-31 | $0 | −$19,150 | — |
| Q1 2015 | 2014-09-30 | $3,400 | −$8,020 | −70.23% |
| Q3 2014 | 2014-03-31 | $19,409 | — | — |
| Q2 2014 | 2013-12-31 | $19,150 | — | — |
| Q1 2014 | 2013-09-30 | $11,420 | — | — |
Biovie r&d spending trends
Over the last five fiscal years, Biovie's r&d spending increased from $2.5M to $14.0M, a change of $11.4M. The latest reported quarter, Q4 2026, shows $3.6M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biovie source filings ↗